caa a22 4500 445338210 CHVBK 20180317142803.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1245/s10434-010-1274-y doi (NATIONALLICENCE)springer-10.1245/s10434-010-1274-y FOXC2 is a Novel Prognostic Factor in Human Esophageal Squamous Cell Carcinoma [Elektronische Daten] [Naohiro Nishida, Koshi Mimori, Takehiko Yokobori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Yuichiro Doki, Masaki Mori] Background: FOXC2 has been implicated in cancer progression through its induction of epithelial-to-mesenchymal transition. We analyzed the clinical significance of FOXC2 in esophageal cancer cases, in which early distant metastasis or invasion to nearby organs is an obstacle to treatment. Methods: Quantitative reverse transcriptase-polymerase chain reaction was used to evaluate FOXC2 mRNA expression in 70 esophageal cancer cases to determine the clinicopathologic significance of FOXC2 expression. Furthermore, we examined associations between FOXC2 expression and matrix metalloproteinases 2 (MMP2) and matrix metalloproteinases 9 (MMP9). We also performed in vitro invasion and migration assays for FOXC2-suppressed esophageal cancer cells. Results: In clinicopathologic analysis, the high-FOXC2 expression group showed a higher incidence of advanced tumor stage, lymph node metastasis, and lymphatic invasion than the low-FOXC2 expression group (P<0.05). In particular, tumor stage exhibited the most remarkable difference (P<0.0001). Expression of MMP2 and MMP9 was far higher in the high-FOXC2 expression group. Furthermore, the high-FOXC2 expression group had a significantly poorer prognosis than did the low expression group (P=0.006). Multivariate analysis indicated that high FOXC2 expression was an independent prognostic factor for survival. Suppression of FOXC2 expression altered the invasive and the migratory ability of esophageal cancer cells in vitro. Conclusions: Our findings suggest that FOXC2 could be an important prognostic indicator for esophageal cancer patients. FOXC2 is directly involved in cancer progression and is associated with poor prognosis in esophageal cancer cases. Society of Surgical Oncology, 2010 Nishida Naohiro Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut Mimori Koshi Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut Yokobori Takehiko Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut Sudo Tomoya Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut Tanaka Fumiaki Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut Shibata Kohei Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut Ishii Hideshi Department of Surgical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan aut Doki Yuichiro Department of Surgical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan aut Mori Masaki Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 535-542 1068-9265 18:2<535 2011 18 10434 https://doi.org/10.1245/s10434-010-1274-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1274-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Nishida Naohiro Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut NATIONALLICENCE 700 1- Mimori Koshi Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut NATIONALLICENCE 700 1- Yokobori Takehiko Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut NATIONALLICENCE 700 1- Sudo Tomoya Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut NATIONALLICENCE 700 1- Tanaka Fumiaki Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut NATIONALLICENCE 700 1- Shibata Kohei Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut NATIONALLICENCE 700 1- Ishii Hideshi Department of Surgical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan aut NATIONALLICENCE 700 1- Doki Yuichiro Department of Surgical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan aut NATIONALLICENCE 700 1- Mori Masaki Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 535-542 1068-9265 18:2<535 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer